Seegene Up 29% In Q1 Revenue...Turned into operating profit and net profit surplus
May 09, 2025
|
According to the preliminary performance disclosure applying the Korean International Financial Reporting Standards (K-IFRS) on the 9th, Seegene's sales in the first quarter of 2025 were 116 billion won, up 29.0% from the same period last year. Operating profit was 14.8 billion won and net profit was 28.9 billion won.
Of the total reagent sales of 94.3 billion won, sales of diagnostic reagents increased 30.4% year-on-year to 83.2 billion won, of which sales of non-COVID diagnostic reagents increased 37.5% to 79.2 billion won. Sales of extraction reagents rose 24.7% to 11.1 billion won, while sales of equipment and other items also rose 25.4% to 21.7 billion won.
Among the sales of diagnostic reagents, respiratory virus (RV) products and respiratory bacterial (PB) products showed solid growth, increasing 44.8% and 130.9%, respectively, compared to the same period last year. It is explained that sales of respiratory products have been strong due to the flu epidemic. Non-respiratory products also increased 35.3% in GI comprehensive products and 31.5% in cervical cancer (human papillomavirus, HPV) related products.
Europe had the highest proportion of sales by region at 64%, followed by Asia at 15%, Korea at 9%, Latin America at 7%, and North America at 4%.
A Seegene official said "Q1 earnings appear to be good on the back of strong sales of respirator products."Since last year, the syndromic campaign promoted in the global market has been showing results, and we are continuing to increase HPV sales in the European screening inspection market, etc."
This article was translated by Naver AI translator.
